COO Cooper Companies Inc.

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (“Cooper”) (Nasdaq: COO), a leading medical device company, published its . The report showcases the company’s initiatives to foster positive change for both people and the planet and provides expanded and updated sustainability performance data.

In 2024, CooperCompanies maintained strong partnerships to reduce its plastic footprint, earned a number of sustainability certifications, and supported employee growth with significant investments in learning and development programs for employees.

“Our 2024 Sustainability Report reflects Cooper’s commitment to help people experience life’s beautiful moments while benefiting people and the planet,” said Al White, Cooper’s President and CEO.

The report is guided by multiple frameworks for evaluating sustainability performance, with continued alignment to the Sustainability Accounting Standards Board (SASB) Standards, a leading investor-focused sustainability reporting framework.

Read more in the Cooper .

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit .

Forward-Looking Statements  

This press release contains “forward-looking statements,” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance, and other statements, of which are other than statements of historical fact, including all statements regarding planned sustainability programs and goals, the anticipated impact of sustainability activities, and product and technology plans, are forward-looking. To identify these statements, look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates,” or “anticipates,” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political, and economic conditions, including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of international conflicts and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates, and our ability to supply product to, or through, affected countries; our substantial and expanding international operations, and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance, and regulatory requirements; compliance costs and potential liability in connection with U.S. and foreign laws and healthcare regulations pertaining to privacy and security of personal information, including, not limited to, those resulting from data security breaches; a major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain; a successful cybersecurity attack; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations, and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the healthcare industry; new competitors, product innovations or technologies; reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes or other litigation; risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemical in our products; risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the our Annual Report on Form 10-K for the fiscal year ended October 31, 2024.

We caution readers that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. 

Contact:

Kim Duncan

Vice President, Investor Relations and Risk Management

925-460-3663



EN
20/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Ben...

CooperCompanies’ 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (“Cooper”) (Nasdaq: COO), a leading medical device company, published its . The report showcases the company’s initiatives to foster positive change for both people and the planet and provides expanded and updated sustainability performance data. In 2024, CooperCompanies maintained strong partnerships to reduce its plastic footprint, earned a number of sustainability certifications, and supported employee growth with signifi...

 PRESS RELEASE

CooperCompanies to Participate in the William Blair Growth Stock Confe...

CooperCompanies to Participate in the William Blair Growth Stock Conference SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at . About CooperCompaniesC...

 PRESS RELEASE

CooperCompanies Appoints Barbara Carbone to Board of Directors

CooperCompanies Appoints Barbara Carbone to Board of Directors SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four...

 PRESS RELEASE

CooperCompanies Announces Release Date for Second Quarter 2025

CooperCompanies Announces Release Date for Second Quarter 2025  SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at . About Coo...

 PRESS RELEASE

CooperCompanies Announces First Quarter 2025 Results

CooperCompanies Announces First Quarter 2025 Results SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch